Q-omics provides the consensus-scored PCAT2 profile across patient tissues and cancer cell-line models. PCAT2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, PCAT2 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PCAT2 RNA expression shows 7,664 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight PAAD, COAD, and READ as cancer lineages where PCAT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCAT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCAT2 survival associations across molecular data types. PCAT2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCAT2 RNA expression–survival associations across cancer types. High PCAT2 expression shows unfavorable associations in PAAD, UCEC, THYM and UVM, but favorable associations in READ and COAD. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for PCAT2 RNA expression.
This table summarizes PCAT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PCAT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCAT2 shows higher tumor expression in COAD, LUSC, LIHC, ESCA, READ and PRAD. The COAD box plot shows higher PCAT2 RNA expression in tumor versus normal tissue (log2 FC = +0.469, t-test p < 0.001).
This table shows molecular features associated with PCAT2 in patient tissues and cancer cell lines. In patient samples, PCAT2 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
